Truist raised the firm’s price target on Encompass Health (EHC) to $135 from $116 and keeps a Buy rating on the shares. The firm remains bullish on the name following Q1 results marked by brisk volumes, better revenue/discharge, strong cost controls and raised FY25 guidance, the analyst tells investors in a research note. Demand trends for Encompass remain robust, occupancy was superb, and payor mix favorable, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health price target raised to $125 from $110 at RBC Capital
- Encompass Health price target raised to $130 from $120 at Raymond James
- Encompass Health price target raised to $130 from $110 at Mizuho
- Encompass Health: Strong Performance and Strategic Expansion Drive Buy Rating
- Encompass Health’s Strong Q1 2025 Performance and Strategic Moves Justify Buy Rating